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Abstract: Denture stomatitis (DS) is an inflammatory status of oral mucosae frequently observed
in denture wearers, and mainly associated with oral overgrowth of Candida albicans. DS is the
cause of multiple visits to the dental office and is thought to enhance the risk of systemic infections.
The treatment of DS mainly relies upon improvement of oral hygiene measures and prescription
of topical or systemic antifungal agents, and disinfectants that, although effective, are not without
drawbacks. Since, in recent years, some probiotics were investigated as a means to contrast oral
colonization by Candida spp., this study was designed to preliminarily evaluate the effects of probiotic
strain Streptococcus salivarius K12, in subjects affected by DS, and the duration of these effects.
Fifty adult denture wearers affected by DS were enrolled and randomly divided into two groups:
the experimental group was instructed to perform careful oral and denture hygiene and to assume the
probiotic preparation for 30 days; the control group received only oral hygiene instructions. Patients
were evaluated for signs of DS at the beginning of the study, at the end of treatment and 30 days later.
Microbiological samples were obtained at the beginning of the study and at the end of treatment
to quantify Candida albicans cells. Experimental treatment reduced clinical signs and symptoms of
DS and the count of C. albicans. The clinical effects of experimental treatment were still evident after
30 days, suggesting that administration of probiotic strain Streptococcus salivarius K12 could be a
promising approach in the treatment of DS.
Keywords: denture stomatitis; Candida albicans; probiotic; Streptococcus salivarius
1. Introduction
Life expectancy significantly increased in industrialized countries in the last century, while natality
progressively reduced [1]; consequently, the proportion of elderly subjects significantly increased, with
evident healthcare issues in all fields of medicine, including dentistry [2,3]. Edentulism (both partial
and total) is among the most frequent dental problems of an aged population, and in many cases it
is treated by removable dentures [4]. An inflammatory status of the oral mucosal areas covered by
the denture is frequently observed in denture wearers. This inflammatory condition is commonly
known as denture stomatitis (DS). The prevalence of DS was reported to range from 15% to over 70%,
depending on variables including: continuous use of the denture, quality of oral and denture hygiene
(frequently limited by dexterity of the subject), adequateness of the denture, and co-morbidities such
as diabetes [5].
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The etiology of DS is multifactorial, but Candida albicans and other fungi of the genus Candida
are believed to be key etiologic factors. Several members of the genus Candida are common members
of oral biofilms and are able to overgrow in the denture microenvironment, inducing inflammation
and acting as promoters of opportunistic polymicrobial infections, frequently observed in DS [5–9].
Clinically DS is characterized by soreness, pain, discomfort, denture mobilization and is consequently
the cause of multiple visits to the dental office. DS is, moreover, believed to be a condition potentially
enhancing the risk of pulmonary and other systemic infections, particularly in institutionalized elderly
subjects [10–12].
The prevention and treatment of DS in many cases relies only upon an examination of the adequacy
of the denture, improvement of oral hygiene measures and a discontinuation of nocturnal wearing of
the denture [13]. Therapeutic strategies based upon the administration of topical or systemic antifungal
agents and disinfectants [14], or upon incorporation of slow release antifungal/antimicrobial agents
into denture base materials [15] were also proposed. Although antifungal drugs proved effective in
relieving clinical signs and symptoms of DS, they are not without drawbacks. In fact, high rates of
early post-treatment relapse and recurrence were reported [16], while prolonged therapeutic regimens
or multiple cycles of treatment greatly enhance the risk of potential systemic adverse effects [17] and
of induction of antifungal drug resistance in resident fungal strains [18], making the treatment of DS
by their means challenging. In recent years the administration of specific probiotic preparations was
investigated as a means to contrast oral colonization by Candida spp. in denture wearers both in the
presence and in the absence of DS, although with contrasting results [19–22].
The present work was consequently designed to preliminarily evaluate if a probiotic preparation,
containing Streptococcus salivarius strain K12 could prove effective in reducing clinical signs and
symptoms of DS and in reducing oral colonization by C. albicans, and if the duration of clinical effects
continued after the end of treatment.
2. Experimental Section
2.1. Studied Subjects and Study Design
Fifty adult human subjects of both sexes were enrolled for this study from a larger population
of denture wearers attending or referred to the Department of Oral and Maxillo-Facial Sciences of
“Sapienza” University of Rome. Inclusion criteria were as follows: presence of at least one totally
edentulous dental arch, presence of a full arch, well-fitting removable acrylic denture, presence of
subjective discomfort/pain in relation to denture, and presence of clinical signs of DS. Exclusion criteria
were as follows: use of adhesives for denture stabilization, use of antibiotics in the last 30 days, presence
of systemic diseases influencing homeostasis of the oral mucosae (i.e., lupus erythematosus, lichen
planus, xerostomia) or significantly influencing immunity (malignancies, transplantations requiring
immunosuppressive therapy).
Upon enrollment in the study patients were informed of the scope of the study and were asked to
sign an informed consent in accordance with criteria of the Helsinki Declaration of 1975, as revised in
2000. The present study was approved by the Ethical Committee of Policlinico Umberto I of Rome
(n. 4790) and registered with the trial identification number ISRCTN14751782. A written informed
consent form was signed by all the patients before their enrollment.
All patients were instructed to perform scrupulous mechanic denture and oral hygiene daily.
More precisely they were instructed to clean the denture with a dedicated brush under a constant flux
of tap water and to carefully brush their teeth, the oral mucosae and tongue with their toothbrush. They
were also instructed to refrain from wearing the denture 24 h a day and invited not to use oral rinses
containing antimicrobial substances. Patients enrolled in the study were subjected to baseline (T-0)
clinical evaluation and microbiological sampling and randomly assigned to either the experimental
group (25 subjects) or to the control group (25 subjects). Patients assigned to the experimental group
(EXP) were invited to perform mechanic denture and oral hygiene as previously explained, and to
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take 1 tablet of Bactoblis® (Pharmaextracta Spa, Pontenure, Piacenza, Italy), containing 109 CFU of the
probiotic strain S. salivarius K12 for 30 days in the evening, just before going to sleep. Patients were
instructed to remove the denture and allow the tablet to dissolve in the mouth, and to refrain from
drinking for the next 60 min.
Patients assigned to the control group (CTR) were invited to perform mechanic denture and
oral hygiene as previously explained for 30 days. All subjects of both groups were instructed not
to wear the denture while sleeping and to maintain the denture within a dedicated box during the
night. At the end of the period of 30 days all patients were subjected to a second (T-30) clinical
evaluation and microbiological sampling, and further instructed to reinstate previous oral and denture
hygiene measures for the next 30 days. At the end of this period they were subjected to further clinical
evaluation (T-60) (Figure 1).
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2.2. Clinical Evaluation
Clinical evaluation included recording of two subjective parameters and one objective index.
Subjective feeling of pain i the oral mucosa and dryness of th mouth w e recorded for each patient.
Answers were rec rded as presence (1) or bsence (0). Each patient was insp te by an xperienced
cli ician in o der t determine the presence nd extension of clinical sign of DS according to Newton’s
assification [23]. This classification of DS describes thre steps of stomatitis according to diffusio and
intensity of clin cal s g s of inflamm tion. Grade 1: pres nce of pin-point hyperemic lesions (localized
simple i flamma ion); grade 2: pre ence diffuse erythema involving most of the mucosa contacting
the denture (generalized simple inflammation); grade 3: presence of inflam tion associated with a
granul r surface of t mucosa contacting the denture (inflammatory papilla y hyp rplasia).
All clinical evaluations were performed separately by three exp rienc d clinicians (C.P., D.D.N.,
and L.T.), and calibrated to provide consistent determination of Newton’s class as follows: twenty
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subjects were selected among those participating in the study. Each examiner independently evaluated
and scored each subject; measures were repeated after 24 h on the same subjects. Values recorded by
the three examiners at the same time were used to calculate inter-examiner reproducibility. Values
recorded by each examiner at different times were used to calculate intra-examiner reproducibility.
Inter- and intra-examiner reproducibility was measured through Cohen’s weighted kappa; values
obtained suggest an almost perfect agreement among the three examiners [24].
2.3. Microbiological Samples
Microbiological samples for detection and quantification of C. albicans cells were obtained from
all patients at T0 and T30 by two methods [25]: (i) by streaking a cotton swab along the apex of the
gingival process for a length of 30 mm in areas with signs of DS; the swab was then inserted in a
sterile polystyrene tube containing 1 mL of Stuarts transport medium; (ii) by instructing each patient
to remove the denture and to rinse vigorously with 10 mL of sterile physiologic saline for 1 min.
The rinse was collected in a sterile 50 mL polypropylene tube. Samples were always stored on ice until
further processing.
2.4. Quantification of Candida Albicans in Samples
Tubes containing swabs for enumeration of C. albicans cells were vortexed for 1 min before
transferring the transport medium to a sterile 1.5 mL polypropylene centrifuge tube. Samples were
then centrifuged at 10,000× g at 4 ◦C for 5 min; the supernatant was removed, and cellular pellets were
suspended in 1 mL of sterile physiologic saline. Tubes containing rinses were centrifuged at 10,000× g
at 4 ◦C for 5 min; the supernatant was then discarded, and pellets were suspended in 1 mL of sterile
physiologic saline. Tenfold dilutions were prepared from all samples, and 0.1 mL of each sample and
of its dilution was plated on BBL Chromagar Candida Medium (Becton Dikinson GmbH, Heidelberg,
Germany). Following incubation for 48 h at 37 ◦C, plates were inspected and colonies of C. albicans
(i.e., green colored colonies) were counted. The development of colonies with phenotypes typical of
non-albicans Candida spp. was always recorded.
2.5. Statistical Analysis
Differences in mean counts of C. albicans in the swab and rinse cultures between the study and
control group at T0 and T30 were analyzed using the Student’s t-test. Differences in terms of DS
according to the Newton’s class were compared using the Mann–Whitney U test. Differences between
groups in the distribution of pain and dryness were compared using the Fisher’s exact test. Statistical
analysis was performed with SPSS 13.0 for Windows. The significance level was set at p ≤ 0.05.
3. Results
3.1. Studied Population
Fifty adult denture wearers of both sexes were selected for this study and randomly assigned to
two groups of 25 subjects. The two groups were comparable for age (EXP mean age 74.3 ± 3.8 years,
age range 68–82, CTR mean age 73.1 ± 3.6 years, age range 67–83, p = 0.26), and gender (males/females:
EXP 13/12, CTR 11/14, p = 0.58) (Table 1). At T0 the EXP and CTR groups were comparable with respect
to clinical parameters, and C. albicans counts. With respect to the degree of DS, as determined by
Newton’s classification, at T0 the EXP group showed a mean score of 2.1 ± 0.6, and the CTR group
a mean score of 2.2 ± 0.6 (p = 0.66). All patients in both groups suffered pain at T0, while 36% of
patients of the EXP group suffered from dryness, as compared to 44% in the CTR group (p = 0.77).
No significant differences were observed at T0 between groups in the mean C. albicans counts in the
swab culture (191.2 CFU/mL in the EXP group vs. 183.8 in the CTR group, p = 0.63) and in the rinse
culture (477.1 vs. 463.9, p = 0.64).
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Table 1. Main characteristics of patients enrolled in the study, divided according to treatment group.
Group
Experimental Control
Age (mean ± SD) 74.3 ± 3.8 73.1 ± 3.6
Age range 68–82 67–83
Gender (Males/Females) 13/12 11/14
Smokers a (%) 24 20
Diabetes b (%) 36 28
Arterial hypertension c (%) 64 52
a Only subjects smoking <10 cigarettes/day were enrolled in the study; b only subjects with diabetes in good control
were enrolled in the study; c only patients under therapy and with arterial pressure level <140/90 mmHg were
enrolled in the study.
3.2. Probiotic S. salivarius Improved Clinical Conditions
Clinical parameters recorded for the two groups at T0, T30 and T60 are reported in Tables 1
and 2. Although careful mechanic denture and oral hygiene according to a standard protocol was
able to significantly improve clinical conditions in the CTR group between T0 and T30, the adjunctive
administration of the probiotic preparation Bactoblis® caused a significantly greater improvement of
objective clinical conditions (Table 1) in the same time lapse. Moreover, when patients of both groups
discontinued therapeutic regimens, and resumed their usual oral hygiene behavior for 30 days (T60),
subjects of the EXP group showed further improvement of clinical conditions while those of the CTR
group showed partial worsening (Table 2).
Table 2. Distribution of denture stomatitis (DS) (according to Newton’s classification) between the
study and control groups at T0 (p = 0.665), T30 (p = 0.005) and T60 (p < 0.001).
Group
Control Experimental
Count Column N % Count Column N %
Newton class at T0 0 0 0.0% 0 0.0%
1 2 8.0% 4 16.0%
2 17 68.0% 15 60.0%
3 6 24.0% 6 24.0%
Newton class at T30 0 6 24.0% 15 60.0%
1 16 64.0% 10 40.0%
2 3 12.0% 0 0.0%
3 0 0.0% 0 0.0%
Newton class at T60 0 4 16.0% 18 72.0%
1 13 52.0% 7 28.0%
2 8 32.0% 0 0.0%
3 0 0.0% 0 0.0%
With respect to the degree of DS, no significant difference was observed at T0, while differences
were statistically significant at T30 (p = 0.005) and at T60 (p < 0.001), with DS being more severe in
the CTR group (Table 1). All patients in both groups suffered pain at T0. At T30 7 out of 25 patients
reported pain in the EXP group (28.0%) against 14 out of 25 in the CTR group (56.0%, p = 0.085).
Differences in pain were significant at T60, with four (16.0%) patients reporting it in the EXP group
against 17 in the CTR group (68.0%, p < 0.001, Table 3).
No significant differences in dryness of mouth were observed between groups at T0 (p = 0.77),
T30 (p = 0.42), and T60 (p = 0.14, Table 3). The higher number of patients suffering from dryness at T30
and T60 in the CTR group can be explained by the higher starting number registered at T0. No patient
in the EXP group reported any adverse effect related to the assumption of Bactoblis®.
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Table 3. Distribution of pain and dryness between groups before treatment (T0), after 30 days of
treatment (T30) and after 30 days after treatment had stopped (T60).
Group
Control Experimental
Count Column N % Count Column N %
Pain T0 No 0 0.0% 0 0.0%
Yes 25 100.0% 25 100.0%
Pain T30 No 11 44.0% 18 72.0%
Yes 14 56.0% 7 28.0%
Pain T60 No 8 32.0% 21 84.0%
Yes 17 68.0% 4 16.0%
Dryness T0 No 14 56.0% 16 64.0%
Yes 11 44.0% 9 36.0%
Dryness T30 No 20 80.0% 23 92.0%
Yes 5 20.0% 2 8.0%
Dryness T60 No 18 72.0% 23 92.0%
Yes 7 28.0% 2 8.0%
3.3. Probiotic S. salivarius Reduced C. albicans Counts
Counts of C. albicans were obtained from all patients at T0 and T30 by collecting two different
samples, a swab streaked for a length of 30 mm on the diseased mucosa underlying the denture and
an oral rinse with 10 mL of sterile physiologic saline. As expected from previous reports [25], counts
obtained from oral rinses were, on average, 2.5 times higher than those obtained from swabs.
While counts of C. albicans obtained at T0 from samples of patients of both the EXP and CTR group
were comparable, analysis of both swab and rinse samples showed that the EXP group underwent a
reduction of about 60% of C. albicans counts between T0 and T30, whereas the reduction in the CTR
group, although significant, was only about 20% (Figure 2). Colonies with phenotypes typical of
non-albicans Candida spp. were observed in many cases but their counts were always low so that they
were considered as not relevant for the purposes of the study.
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Figure 2. Candida albicans counts before (T0) and after 30 days treatment regimens (T30) with (EXP) and
without (CTR) probiotic S. salivarius BLIS®K12. C. albicans counts obtained by two distinct sampling
procedures (swab and rinse) are represented in the plot and reported in the explanatory table as colony
forming units/ml (CFU/mL) means (±standard deviation). Significance of differences between single
groups of data was calculated by the Student T test and is reported in the table as values of P.
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4. Discussion
The present work was designed to preliminarily evaluate the potential effectiveness of combining
scrupulous oral and denture hygiene with the administration of a probiotic preparation, containing
Streptococcus salivarius K12 for the treatment of DS in patients wearing well-fitting full arch dentures.
DS is a multifactorial inflammatory disease of the oral mucosal areas covered by the denture, in which
an overgrowth of C. albicans and other opportunistic fungal species normally found in the oral biofilm,
is believed to play a key etiologic role [5,6,26]. DS is the cause of multiple visits to the dental office for
pain, sensation of dryness of the mouth, discomfort and denture mobilization and is also believed to
enhance the risk of pulmonary and other systemic infections [10–12]. C. albicans, as many other fungal
species, is a normal colonizer of mucosal surfaces including the oral mucosa [8], although in healthy
subjects its counts are low. Some clinical conditions, as for example the presence of acrylic bases of
removable prostheses and a diminished hygienic skill favored by ageing, are known to promote a
significant overgrowth of resident fungal species and of C. albicans in particular, thus promoting the
onset of DS [6–8,16].
The availability of effective preventative and therapeutic approaches for DS is consequently
important. As a direct consequence of the multifactorial nature of DS, its treatment may rely on
different approaches, including examination and correction of the denture base, discontinuation of
nocturnal wearing of the denture, improvement of oral and denture hygiene measures [13]. Other
strategies could be the administration of topical or systemic antifungal agents and disinfectants [14],
or the incorporation of slow release antifungal/antimicrobial agents into denture base materials [15].
Despite its multifactorial etiology, the main etiological factor and the principal cause of extensive
inflammation observed in DS is certainly the colonization of the denture base and of the underlying
mucosa by Candida spp. and other fungal species [26]. Consequently, the administration of antifungal
drugs is highly effective in relieving clinical signs and symptoms of DS. Nevertheless, the use of
such drugs is not without drawbacks, since short term treatments are affected by high rates of early
post-treatment relapse and recurrence [16]. Furthermore, prolonged or repeated therapeutic regimens
enhance the risk of systemic adverse effects [17] and are likely to induce antifungal drug resistance in
resident fungal strains [18]. It is well known that the administration of probiotics can be beneficial for
patients suffering for mucosal candidiasis [27].
Previous studies have already shown that the assumption of some, but not all [22], probiotic
preparations can reduce symptoms of DS [19–21], and Candida colonization levels in healthy denture
wearers [19,20] and in subjects affected by DS [21]. However, common probiotic strains of the genus
Lactobacillus have few chances to exert prolonged protective activity since they are not adapted to
be oral colonizers. To overcome this limitation, studies were recently performed to isolate probiotic
Lactobacillus strains directly from the oral cavity [28]. As an alternative strategy, probiotic strains were
searched among normal pioneer colonizers of the oral cavity as S. salivarius [29]. S. salivarius strain K12
is considered as the prototype probiotic strain of this species. It was originally selected for its ability
to inhibit Streptococcus pyogens, but it was subsequently shown to possess several other interesting
activities, including inhibitory activity on Candida spp. [29,30]. Although data on this matter are still
incomplete, several probiotic strains were shown to be able to inhibit biofilm growth, and expression
of virulence and resistance genes of C. albicans [20,30–33].
These considerations prompted us to preliminarily evaluate the effectiveness of a probiotic
preparation containing S. salivarius strain K12 in the treatment of DS. Inclusion/exclusion criteria were
designed to minimize the influence of factors other than microbial dysbiosis due to inadequate oral
hygiene on the presence of clinical signs and symptoms of DS. Subjects wearing not-well-fitting dentures
were excluded, as well as subjects affected by diseases altering immunity and oral homeostasis. In the
selection of patients, attention was paid to minimize the possible interference of potential confounders.
Consequently, in addition to the rigid application of inclusion/exclusion criteria, attention was dedicated
to include only patients in apparent good conditions: diabetic patients with high glycemic levels,
patients with arterial hypertension not well controlled by drugs (i.e., pressure levels > 140/90 mmHg)
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and patients smoking >10 cigarettes/day were excluded from the study. Nevertheless diabetes, arterial
hypertension and smoking were not included as variables in the statistical analysis.
Due to the preliminarily nature of this study, the CTR group was not designed to receive a placebo;
this could have influenced perception of subjective symptoms between the two groups of patients.
As expected, our experimental data confirm that, in the absence of repeated trauma due to
inadequacy of the denture base or too prolonged denture wearing, improvement of the oral and
denture hygiene procedure reduces clinical signs and symptoms of DS and reduces oral colonization
by C. albicans [13,14]. Moreover, data show that the effectiveness of oral and denture hygiene alone is
limited in time. In fact, when (after T30) patients of the CTR group were invited to resume their previous
habits with the dentures, their clinical conditions worsened significantly. Although microbiological
samples were not analyzed at T60, it can be considered plausible, in accordance with data from the
literature [25], that clinical relapse was paralleled by an increase in oral C. albicans counts.
Experimental data show that when improved oral and denture hygiene procedures were flanked
by the administration of a preparation of the probiotic strain S. salivarius K12, a significantly greater
improvement of clinical conditions and a higher reduction of oral C. albicans counts were obtained in
the EXP group at T30. Interestingly and unexpectedly, clinical evaluations performed at T60, when
patients of the EXP group had discontinued treatment for 30 days and had resumed previous oral
and denture hygiene habits, revealed a further improvement of clinical conditions, as opposed to the
partial relapse observed in the CTR group. These data suggest that S. salivarius K12 could be able to
colonize oral mucosa at least for some weeks after discontinuation of treatment and consequently
exhibit a prolonged anti-Candida action. Unfortunately, microbiological sampling was not planned for
T60 and consequently this aspect will deserve future further investigations. A prolonged presence
of the probiotic strain would be in accordance with the well-known role of S. salivarius as a pioneer
colonizer of the human oral cavity [29]. The effective duration of oral colonization by S. salivarius
K12 after 30 days of treatment and the consequent duration of its anti-Candida activity will be the
object of future investigations using specific molecular methods that were recently made available [34].
Future studies will also be necessary to elucidate the cellular and molecular mechanisms underlying
the clinical and microbiological effects of S. salivarius K12 on DS described in this paper.
5. Conclusions
The present work was designed to preliminarily evaluate the clinical and microbiological effects
of a probiotic preparation, containing S. salivarius K12, in Candida albicans-positive subjects affected by
DS, and the duration of clinical effects.
Data presented in this paper confirm that, at least in subjects wearing well-fitting full-arch dentures
and affected by DS, reinforcement of oral and denture hygiene procedures coupled with administration
of a probiotic preparation containing S. salivarius K12 is effective in reducing symptoms and clinical
signs of DS, and significantly reduces oral colonization by C. albicans. The clinical effects associated
with the administration of S. salivarius K12 persist for at least 30 days after discontinuation of treatment.
The tested probiotic preparation could consequently prove as a valid and safe aid in combination with
the improvement of oral and denture hygiene measures for the treatment of DS.
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